Cancer Research

Lytix Biopharma announces positive Phase I data for LTX-315

10 May 2021

Lytix Biopharma has announced promising full data results from a Phase I study of its lead candidate LTX-315 lysing solid tumours, which have been published in Clinical Cancer Research. The study was an open-label multicentre study of LTX-315 with multiple intralesional injections in patients with solid tumours for whom alternative treatment options were not available […]

Global hub for cancer research, treatment and commercial enterprise

10 May 2021

Andy Carr, Business Development Manager at The Institute of Cancer Research, London, introduces the new Innovation Gateway at The London Cancer Hub in Sutton, south London, to DDW’s Megan Thomas. MT: I understand the establishment of the Innovation Gateway is underway. What is the progress and when is it due to open? AC: It’s progressing […]

Janssen seeks approval for refractory multiple myeloma drug

7 May 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. The application is supported by […]

First large study of immunotherapy in black cancer patients

21 April 2021

A new collaboration between Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute will help oncologists learn whether black and white cancer patients respond differently to immunotherapy treatment and seeks to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a two-year, $2.08 million grant from the […]

Researchers identify new role for protein in treatment of cancer

19 April 2021

In a study by Yale Cancer Centre, researchers report on the discovery of a new role for STimulator of INterferon Genes, or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumour DNA damage response. The findings may lead […]

Karen Vousden wins first Women in Cancer Research award

15 April 2021

Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement of women in cancer research. […]

Scientists discover ‘jumping’ genes can protect against blood cancers

12 April 2021

New research has uncovered an unexpected role for so-called “jumping” genes that are a source of genetic mutations responsible for many human diseases. In the new study from Children’s Medical Centre Research Institute at UT Southwestern (CRI), scientists discovered that these DNA sequences, also known as transposons, can protect against certain blood cancers. These findings, […]

Virus therapy shows promise against inoperable skin cancers

12 April 2021

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a coxsackievirus, to infect and kill […]

Kancera’s blockers may pave the way for treatment for ovarian cancer

12 April 2021

Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian cancer. The disease affects over […]

First AI-designed immuno-oncology drug enters clinical trials

9 April 2021

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s next generation 3-D evolutionary AI-design […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free